Development of HPV16 mouse and dog models for more accurate prediction of human vaccine efficacy.
Fiche publication
Date publication
juin 2023
Journal
Laboratory animal research
Auteurs
Membres identifiés du Cancéropôle Est :
Dr HERAULT Yann, Dr SORG Tania
Tous les auteurs :
Totain E, Lindner L, Martin N, Misseri Y, Iché A, Birling MC, Sorg T, Herault Y, Bousquet-Melou A, Bouillé P, Duthoit C, Pavlovic G, Boullier S
Lien Pubmed
Résumé
Animal models are essential to understand the physiopathology of human diseases but also to evaluate new therapies. However, for several diseases there is no appropriate animal model, which complicates the development of effective therapies. HPV infections, responsible for carcinoma cancers, are among these. So far, the lack of relevant animal models has hampered the development of therapeutic vaccines. In this study, we used a candidate therapeutic vaccine named C216, similar to the ProCervix candidate therapeutic vaccine, to validate new mouse and dog HPV preclinical models. ProCervix has shown promising results with classical subcutaneous murine TC-1 cell tumor isografts but has failed in a phase II study.
Mots clés
Canine model, Genetically modified mouse tools, HPV, Immunology, Preclinical research, Vaccine validation
Référence
Lab Anim Res. 2023 06 12;39(1):14